Heikinheimo O, Archer D F
University of Helsinki, Finland.
Clin Obstet Gynecol. 1996 Jun;39(2):461-8. doi: 10.1097/00003081-199606000-00019.
Use of standard estrogen-progestin contraception remains problematic in several subgroups of patients (e.g., those in whom exogenous estrogens are contraindicated, such as survivors of hormone-dependent cancer, or patients with endometriosis or uterine fibroids). In addition, the postcoital contraception, even if already available, remains at least underused. Additionally, continuous intake of contraceptive steroids is under increasing scrutiny. Would antiprogestins, and specifically the applications of mifepristone such as the ones reviewed in this article offer significant improvements at such problematic occasions? The most attractive novel contraceptive application of mifepristone is that of emergency postcoital contraception after unprotected intercourse. In addition, various options in the endometrial category, specifically those requiring drug administration only during a limited time, might be used in the future. Mifepristone might offer contraceptive and therapeutic relief to patients suffering from endometriosis or uterine fibroids, both conditions that have been shown to benefit from mifepristone therapy. However, the use of mifepristone in contraceptive preparations that are widely available would pose an additional problem of possible misuse of the compound, the reason for currently limiting access to mifepristone. However, such risk should be easily avoidable in the case of postcoital contraception in which only one dose of mifepristone is needed. Regarding the future of mifepristone, and more broadly that of antiprogestins in contraception, the authors believe that they will have a place in the future contraceptive armament. As already emphasized, the strongest clinical areas are those of immediate postcoital and endometrial contraception. Additional studies evaluating parenteral modes of administration, the long-term endometrial effects, and safety and metabolic effects of prolonged antiprogestin administration are needed before mifepristone can be considered a part of the contraceptive arena.
在几个患者亚组中,使用标准的雌激素 - 孕激素避孕方法仍然存在问题(例如,那些禁忌使用外源性雌激素的患者,如激素依赖性癌症幸存者,或患有子宫内膜异位症或子宫肌瘤的患者)。此外,即使已有性交后避孕措施,但至少仍未得到充分利用。此外,连续服用避孕类固醇受到越来越多的审视。抗孕激素,特别是米非司酮的应用(如本文所综述的那些应用),在这些有问题的情况下会带来显著改善吗?米非司酮最具吸引力的新型避孕应用是无保护性交后的紧急性交后避孕。此外,子宫内膜类别的各种选择,特别是那些仅在有限时间内需要给药的选择,未来可能会被使用。米非司酮可能为患有子宫内膜异位症或子宫肌瘤的患者提供避孕和治疗缓解,这两种疾病已被证明可从米非司酮治疗中获益。然而,在广泛可用的避孕制剂中使用米非司酮会带来该化合物可能被滥用的额外问题,这也是目前限制米非司酮获取的原因。然而,在性交后避孕的情况下,仅需一剂米非司酮,这种风险应该很容易避免。关于米非司酮的未来,更广泛地说,关于抗孕激素在避孕中的未来,作者认为它们在未来的避孕手段中会占有一席之地。如前所述,最强的临床应用领域是即时性交后避孕和子宫内膜避孕。在米非司酮被视为避孕领域的一部分之前,还需要进行更多研究来评估其肠胃外给药方式、长期子宫内膜影响以及长期抗孕激素给药的安全性和代谢影响。